Brussels, 11/03/2014 (Agence Europe) - On Monday 10 March, the European Commission awarded €2 million to German biopharmaceutical company CureVac GmbH for developing novel technology to produce life-saving vaccines that can be kept stable at any ambient temperature.
This is the first time the EU is offering such a prize for innovation. European Commissioner for Research and Innovation Maire Geoghegan-Quinn said: “CureVac's success opens up the possibility of a real European...